How can the US catch up on biosimilars? – MedCity News

Getty Images

Biosimilars are a growing share of the U.S. pharmaceuticals market. But while there are at least 240 biosimilars in the development pipeline, just nine have achieved FDA approval and only three have reached the market.

What needs to change for more biosimilars to enter the U.S. market?

Read the full story in MedCity News.

Advertisements

What will it take to 3-D print organs? – NeoLife

Sebastian Kaulitzki/Shutterstock; Scientific Reports

Every day in the U.S., about 22 people die waiting for an organ transplant. If scientists could 3-D print organs like kidneys, livers and hearts, all those lives could be saved. For years, people have been touting personalized organ printing as the future.

But despite decades of promising work in bioengineered bladders and other kinds of human tissue, we’re not close to having more complicated organs made from scratch. Harvard professor Jennifer Lewis, a leader in advanced 3-D printing of biological tissue, has only recently developed the ability to print part of a nephron, an individual unit of a kidney.

I asked Lewis what it will take to someday print a full kidney or a similarly complex organ.

Read the full story in NeoLife.

Artificial Intelligence Offers a Better Way to Diagnose Malaria

Image credit: Intellectual Ventures Laboratory

An algorithm for spotting malaria under the microscope could bring accurate, rapid diagnosis to understaffed areas.

For all our efforts to control malaria, diagnosing it in many parts of the world still requires counting malaria parasites under the microscope on a glass slide smeared with blood. Now an artificial intelligence program can do it more reliably than most humans.

Read the full article in MIT Technology Review.

Gel scaffold paves way for 3D printing of biological organs

3D printing needle creates intricate objects in soft gels

To improve 3D printing, simply add gel. A fresh technique uses one to support complex shapes that would fall apart under their own weight in normal 3D printing.

This new-found combination of strength and delicacy will be crucial if we’re ever to print the biological structures that make up organs, blood vessels and other tissue.

Read the full article in New Scientist.

Gene-Editing Startup Raises $120 Million to Apply CRISPR to Medicine

Editas Medicine, a company at the forefront of developing the gene-editing technology known as CRISPR, has raised $120 million to create new treatments for conditions including cancer, retinal disease, and sickle-cell anemia.

Monday’s announcement reflects a surge of interest in CRISPR, a technology that is only a few years old. It also serves to clarify the goals and strategy of Editas, which was founded by some of the most prominent inventors of the gene-editing system, including Feng Zhang, a researcher at the Broad Institute of Harvard and MIT.

Read the full article in MIT Technology Review.